Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A First-Class Degrader Candidate Targeting Both KRAS G12D and G12V Mediated by CANDDY Technology Independent of Ubiquitination.

Molecules (Basel, Switzerland) - 24 Jul 2023

Miyamoto-Sato Etsuko, Imanishi Satoshi, Huang Lijuan, Itakura Shoko, Iwasaki Yoichi, Ishizaka Masamichi

Abstract excerpt

"Undruggable" targets such as KRAS are particularly challenging in the development of drugs. We devised a novel chemical knockdown strategy, CANDDY (Chemical knockdown with Affinity aNd Degradation DYnamics) technology, which promotes protein degradation using small molecules (CANDDY molecules) that are conjugated to a degradation tag (CANDDY tag) modified from proteasome inhibitors. We demonstrated that CANDDY...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease Models, Animal
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to Ubiquitination

Source

Open in PubMed Open full text

Identifiers

PMID: 37513471
DOI: 10.3390/molecules28145600
PMCID: PMC10386196

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A First-Class Degrader Candidate Targeting Both KRAS G12D and G12V Mediated by CANDDY Technology Independent of Ubiquitination.PMID 37513471Read ↗

Small-molecule degraders for oncogenic KRASG12C and pan-KRAS mutations.Semantic proximity Read ↗

A pan-KRAS degrader for the treatment of KRAS-mutant cancersSemantic proximity Read ↗

A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS.Semantic proximity Read ↗

Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers.Semantic proximity Read ↗

Discovery of highly potent and selective KRASG12C degraders by VHL-recruiting PROTACs for the treatment of tumors with KRASG12C-Mutation.Semantic proximity Read ↗

Efficient targeted oncogenic KRASG12C degradation via first reversible-covalent PROTAC.Semantic proximity Read ↗

Heterobifunctional proteomimetic polymers for targeted protein degradationSemantic proximity Read ↗

Exquisitely Specific anti-KRAS Biodegraders Inform on the Cellular Prevalence of Nucleotide-Loaded StatesSemantic proximity Read ↗

Clinical Translation of Targeted Protein DegradersSemantic proximity Read ↗

Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancerSemantic proximity Read ↗

bioPROTACs establish RAS as a degradable target and provide novel RAS biology insightsSemantic proximity Read ↗

Mutant KRAS is a druggable target for pancreatic cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.